Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial

被引：0
|
作者：
J Cummings
M Zweifel
N Smith
P Ross
J Peters
G Rustin
P Price
M R Middleton
T Ward
C Dive
机构：
[1] Clinical and Experimental Pharmacology Group,Department of Medical Oncology
[2] Manchester Cancer Research Centre,Academic Department of Radiation Oncology
[3] Paterson Institute for Cancer Research,University of Oxford Department of Medical Oncology
[4] University of Manchester,undefined
[5] Manchester,undefined
[6] Mount Vernon Cancer Centre,undefined
[7] Middlesex,undefined
[8] Northwood HA6 2RN,undefined
[9] UK,undefined
[10] Drug Development Office,undefined
[11] Cancer Research UK,undefined
[12] 61 Lincoln's Inn Fields,undefined
[13] London WC2A 3PX,undefined
[14] UK,undefined
[15] University of Manchester,undefined
[16] The Christie NHS Foundation Trust,undefined
[17] Oxford Biomedical Research Centre Cancer Theme,undefined
[18] Churchill Hospital,undefined
来源：
British Journal of Cancer | 2012年 / 106卷
关键词：
OXi4503; vascular disrupting agent; phase I trial; cell death mechanisms; M30 ELISA; M65 ELISA;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1766 / 1771
页数：5
相关论文
共 50 条
  • [41] Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors
    LoRusso, Patricia M.
    Gadgeel, Shirish M.
    Wozniak, Antoinette
    Barge, Alan J.
    Jones, Helen K.
    DelProposto, Zachary S.
    DeLuca, Pamela A.
    Evelhoch, Jeffrey L.
    Boerner, Scott A.
    Wheeler, Catherine
    [J]. INVESTIGATIONAL NEW DRUGS, 2008, 26 (02) : 159 - 167
  • [42] Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors
    Patricia M. LoRusso
    Shirish M. Gadgeel
    Antoinette Wozniak
    Alan J. Barge
    Helen K. Jones
    Zachary S. DelProposto
    Pamela A. DeLuca
    Jeffrey L. Evelhoch
    Scott A. Boerner
    Catherine Wheeler
    [J]. Investigational New Drugs, 2008, 26 : 159 - 167
  • [43] Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors
    Beerepoot, LV
    Radema, SA
    Witteveen, EO
    Thomas, T
    Wheeler, C
    Kempin, S
    Voest, EE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (10) : 1491 - 1498
  • [44] A Phase I Clinical Trial of LUM015: A Protease-activated Fluorescent Imaging Agent to Detect Cancer during Surgery
    Whitley, M. J.
    Cardona, D. M.
    Blazer, D. G.
    Hwang, E.
    Greenup, R. A.
    Mosca, P. J.
    Cahill, J.
    Mito, J. K.
    Cuneo, K. C.
    Larrier, N.
    O'Reilly, E.
    Spasojevic, I.
    Riedel, R. F.
    Eward, W. C.
    Griffith, L. G.
    Bawendi, M. G.
    Kirsch, D. G.
    Brigman, B. E.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S11 - S12
  • [45] Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.
    Radema, SA
    Beerepoot, LV
    Witteveen, E
    Thomas, T
    Kempin, S
    Wheeler, C
    Voest, EE
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6147S - 6148S
  • [46] Transient Retinal Effects of 5,6-Dimethylxanthenone-4-acetic Acid (DMXAA, ASA404), an Antitumor Vascular-Disrupting Agent in Phase I Clinical Trials
    Jameson, Michael B.
    Sharp, Dianne M.
    Sissingh, Jennifer I.
    Hogg, Christopher R.
    Thompson, Paul I.
    McKeage, Mark J.
    Jeffery, Mark
    Waller, Susan
    Acton, Gary
    Green, Colin
    Baguley, Bruce C.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2009, 50 (06) : 2553 - 2559
  • [47] URINARY AND ERYTHROCYTE POLYAMINES DURING THE EVALUATION OF ORAL ALPHA-DIFLUOROMETHYLORNITHINE IN A PHASE-I CHEMOPREVENTION CLINICAL-TRIAL
    PENDYALA, L
    CREAVEN, PJ
    PORTER, CW
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 1993, 2 (03) : 235 - 241
  • [48] Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non-Small-Cell Lung Cancer
    Lara, Primo N., Jr.
    Douillard, Jean-Yves
    Nakagawa, Kazuhiko
    von Pawel, Joachim
    McKeage, Mark J.
    Albert, Istvan
    Losonczy, Gyoergy
    Reck, Martin
    Heo, Dae-Seog
    Fan, Xiaolin
    Fandi, Abderrahim
    Scagliotti, Giorgio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (22) : 2965 - 2971
  • [49] Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma
    Shi, Ming
    Zhang, Bing
    Tang, Zi-Rong
    Lei, Zhou-Yun
    Wang, Hui-Fen
    Feng, Yong-Yi
    Fan, Zhen-Ping
    Xu, Dong-Ping
    Wang, Fu-Sheng
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2004, 10 (08) : 1146 - 1151
  • [50] Autologous Stem Cell Transplantation Promotes Mechanical Stretch Induced Skin Regeneration: A Randomized Phase I/II Clinical Trial
    Zhou, Shuang-Bai
    Zhang, Guo-You
    Xie, Yun
    Zan, Tao
    Gan, Yao-Kai
    Yao, Caroline A.
    Chiang, Cheng-An
    Wang, Jing
    Liu, Kai
    Li, Hua
    Zhou, Jia
    Yang, Mei
    Gu, Bin
    Xie, Feng
    Pu, Lee Q.
    Magee, William P.
    Li, Qing-Feng
    [J]. EBIOMEDICINE, 2016, 13 : 356 - 364
12345